Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. It is focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using its drug delivery technologies. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of more than 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. Its other pipeline drug candidates: GTX-102 and GTX-101. GTX-102 is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia. GTX-101 is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.